CJC1295/Ipamorelin (No DAC)
CJC-1295 (No DAC) + Ipamorelin blend — synergistic GH secretagogue stack.
CJC/Ipamorelin — Growth Hormone Research Profile
In secretagogue pharmacology, This blend combines CJC-1295 (Modified GRF 1-29), a GHRH analog that amplifies GH pulse amplitude, with Ipamorelin, a selective ghrelin receptor agonist that triggers GH release without significant cortisol or prolactin elevation. Together they produce synergistic GH output through dual pathways.
Primary research applications for CJC/Ipamorelin include synergistic growth hormone release, minimal cortisol elevation, improved body composition, better sleep quality. As a Growth Hormone compound, it is studied in the context of growth hormone, ghrh, secretagogue — areas where its mechanism of action has the most direct relevance in preclinical models.
In standard research protocols, CJC/Ipamorelin is administered at 100–200 mcg CJC + 200–300 mcg Ipamorelin, 2–3×/week before sleep, with a half-life of CJC ~30 min; Ipamorelin ~2 hours. This product is supplied by Apollo Peptide Sciences as lyophilized powder with independent third-party Certificate of Analysis (COA) documentation confirming 99%+ purity and correct molecular identity on every batch. CJC1295/Ipamorelin (No DAC) is sold strictly for laboratory and educational use only — it is not FDA-approved for human therapeutic use and is not intended for human consumption, clinical application, or use in animals.
🔬 Mechanism of Action
CJC-1295 works upstream of growth hormone itself — which is what makes it mechanistically interesting. It binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating adenylyl cyclase activity and cAMP accumulation, which triggers GH synthesis and secretion. The result is elevated circulating GH that mirrors the body's natural pulsatile pattern rather than the supraphysiological spike you'd get from injecting exogenous GH. This distinction matters: natural pulsatile GH release preserves somatostatin feedback, the built-in brake that prevents overstimulation. The no-DAC version stocked here has a half-life of roughly 30 minutes, which is ideal for pulse-dosing protocols designed to synchronize with natural GH secretion windows — typically fasted states and the pre-sleep period when endogenous GH peaks are highest. Downstream of GH secretion, the liver responds by producing IGF-1 (insulin-like growth factor 1), which mediates most of GH's anabolic effects on skeletal muscle, adipose tissue, and bone. Rising IGF-1 is the practical biomarker researchers use to confirm that CJC-1295 is producing meaningful GH axis activation.
Applications & Benefits
Effect Timeline
Expected milestones based on published preclinical data.
First amplified GH pulses detected. Slight IGF-1 elevation begins; anabolic signaling pathways activate.
IGF-1 levels plateau at elevated baseline. Protein synthesis increases; recovery from training improves noticeably.
Lean mass accumulation measurable. Fat oxidation increases; sleep quality improvements typically reported.
Maximum body composition improvements at sustained elevated GH/IGF-1 levels. Anti-aging mechanisms fully engaged.
First amplified GH pulses detected. Slight IGF-1 elevation begins; anabolic signaling pathways activate.
IGF-1 levels plateau at elevated baseline. Protein synthesis increases; recovery from training improves noticeably.
Lean mass accumulation measurable. Fat oxidation increases; sleep quality improvements typically reported.
Maximum body composition improvements at sustained elevated GH/IGF-1 levels. Anti-aging mechanisms fully engaged.
Timelines are derived from preclinical animal studies. Individual results in laboratory settings may vary. For educational purposes only.
Dosing Protocol
Dosing information is derived from published animal studies and is provided for educational purposes only.
Key Study Findings
Human pharmacokinetic studies confirmed sustained GH elevation for over 7 days with the DAC form — the longest documented duration for any GHRH analog
Dose-dependent IGF-1 increases documented in study subjects, confirming downstream hepatic GH signaling is intact and appropriately amplified
Pulsatile GH release pattern preserved with the no-DAC version — neuroendocrine feedback loops including somatostatin inhibition remain active, a key distinction from direct GH administration
Improved nitrogen retention and lean mass markers observed alongside IGF-1 elevation in research subjects, indicating functional downstream anabolic signaling
No-DAC form retains full GHRH receptor activity with a pulse-friendly 30-minute half-life, making it the preferred format for time-sensitive multi-dose GH secretagogue protocols
Synergistic GH output documented when CJC-1295 is combined with GHSR agonists like Ipamorelin — dual-pathway stimulation produces greater total GH release than either compound alone
Frequently Asked Questions
Why choose CJC-1295 without DAC over the DAC version?
The no-DAC version (Modified GRF 1-29) is built for researchers who want to mimic the natural pulsatile rhythm of GH release. Because it clears the system in roughly 30 minutes, each dose triggers a discrete GH pulse — similar to how your body naturally releases GH in waves throughout the day. The DAC version's extended half-life (6–8 days) leads to continuous, tonic GH elevation, which some researchers argue disrupts the body's natural feedback rhythms. If you're designing a protocol around physiological GH patterns — especially when paired with a GHSR agonist like Ipamorelin — the no-DAC version is typically the preferred research tool.
How does CJC-1295 actually increase IGF-1 levels?
CJC-1295 stimulates GH release from the pituitary, and GH's primary downstream effect is signaling the liver to produce IGF-1 (insulin-like growth factor 1). IGF-1 is the hormone that mediates most of GH's anabolic effects — muscle protein synthesis, fat oxidation, bone density support. When you see IGF-1 levels rise in CJC-1295 studies, that's confirmation that the GH signal is being received and amplified through the hepatic axis. Researchers use IGF-1 as a practical biomarker for GH activity because it's easier to measure reliably than pulsatile GH itself.
Is stacking CJC-1295 with Ipamorelin actually synergistic, or just marketing?
There's a real mechanism behind it. CJC-1295 and Ipamorelin hit different receptors in the same pathway. CJC-1295 binds GHRH receptors on pituitary somatotrophs — the 'go' signal for GH release. Ipamorelin binds GHSR (the ghrelin receptor), which amplifies the magnitude of each GH pulse. Together, one compound provides the stimulus for GH release and the other amplifies the response, producing greater total GH output than either alone. Studies have documented this synergistic effect, which is why the CJC-1295 + Ipamorelin combination appears so consistently in growth hormone secretagogue research protocols.
What role does sleep timing play in CJC-1295 dosing protocols?
Sleep timing is one of the most discussed aspects of CJC-1295 without DAC protocols — and it's not arbitrary. The body's largest natural GH pulse occurs approximately 60–90 minutes after falling asleep, during the first wave of deep (slow-wave) sleep. Dosing CJC-1295 no-DAC 15–30 minutes before sleep is designed to amplify that natural pulse rather than create a separate, out-of-cycle GH spike. The idea is to work with the body's existing rhythm rather than impose an artificial pattern on top of it. Some researchers also include a fasted morning dose to catch a second natural GH window. This timing sensitivity is one of the main practical differences between the no-DAC and DAC versions — with the longer-acting DAC form, precise timing matters less.
Reconstitution Calculator
Calculate exact BAC water volume and dose measurements for CJC1295/Ipamorelin (No DAC).
For laboratory use only. This calculator is a reference tool — verify all calculations before use. Always use sterile technique with bacteriostatic water and sterile syringes.
💎CJC1295/Ipamorelin (No DAC) for Looksmaxxing
CJC-1295 is central to body recomposition looksmaxxing — the most studied GHRH analog for optimizing growth hormone output. In looksmaxxing protocols it's almost always paired with Ipamorelin to achieve synergistic GH pulse amplification. The resulting increases in GH and IGF-1 drive lean mass accretion, reduce fat mass (particularly visceral and subcutaneous), and improve skin quality through IGF-1-mediated collagen synthesis. It is the foundation of any appearance-focused growth hormone protocol.
Effectiveness Profile
Relative effectiveness scores derived from published preclinical literature across key endpoints.
Scores are qualitative aggregates from animal and in vitro studies and are not a medical claim. For educational purposes only.
The Anabolic Signaling Cascade
Pituitary release of growth hormone in response to GHRH + ghrelin receptor stimulation.
Hepatic IGF-1 production binds insulin-like growth factor receptors in target tissue.
Phosphatidylinositol 3-kinase cascade activates downstream survival and growth signaling.
Mammalian target of rapamycin drives ribosomal translation — the molecular endpoint of anabolic growth.
CJC/Ipamorelin at a Glance
Related Topics
CJC/Ipamorelin
For educational use only · Verified vendor
